Biogen Inc. (NASDAQ:BIIB - Get Free Report) insider Priya Singhal sold 93 shares of the firm's stock in a transaction dated Tuesday, April 2nd. The shares were sold at an average price of $213.09, for a total transaction of $19,817.37. Following the transaction, the insider now owns 4,886 shares of the company's stock, valued at $1,041,157.74. The transaction was disclosed in a document filed with the SEC, which is available at this link.
Priya Singhal also recently made the following trade(s):
- On Thursday, February 22nd, Priya Singhal sold 262 shares of Biogen stock. The shares were sold at an average price of $221.23, for a total transaction of $57,962.26.
- On Friday, February 16th, Priya Singhal sold 108 shares of Biogen stock. The stock was sold at an average price of $221.49, for a total transaction of $23,920.92.
- On Monday, February 12th, Priya Singhal sold 419 shares of Biogen stock. The stock was sold at an average price of $239.45, for a total transaction of $100,329.55.
Biogen Trading Down 0.6 %
BIIB opened at $206.38 on Thursday. The stock has a market capitalization of $30.00 billion, a PE ratio of 25.86, a P/E/G ratio of 1.73 and a beta of -0.02. The firm's fifty day moving average price is $226.85 and its 200 day moving average price is $240.75. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.00 and a quick ratio of 1.26. Biogen Inc. has a 12-month low of $205.36 and a 12-month high of $319.76.
Charles Payne’s Gift to Stock Investors
From Unstoppable Prosperity | Ad
Right now, millions of good honest folks are feeling the squeeze.
Last year's terrible market did a number on their accounts.
Stock values plunged.
Retirement accounts lost too.
Watch Insider's Advantage Event Tuesday at 4:00 PM ET
Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Tuesday, February 13th. The biotechnology company reported $2.95 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.18 by ($0.23). The company had revenue of $2.39 billion during the quarter, compared to analyst estimates of $2.47 billion. Biogen had a net margin of 11.81% and a return on equity of 14.91%. During the same period in the prior year, the company earned $4.05 earnings per share. As a group, research analysts expect that Biogen Inc. will post 15.48 EPS for the current fiscal year.
Analyst Ratings Changes
A number of equities research analysts have recently commented on the stock. Wedbush lifted their price target on shares of Biogen from $239.00 to $245.00 and gave the stock a "neutral" rating in a report on Monday, February 12th. Truist Financial reiterated a "buy" rating and set a $340.00 price target on shares of Biogen in a report on Monday, March 25th. Raymond James raised shares of Biogen from a "market perform" rating to an "outperform" rating and set a $283.00 target price on the stock in a research report on Thursday, December 7th. Robert W. Baird decreased their target price on shares of Biogen from $333.00 to $316.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 14th. Finally, Oppenheimer decreased their target price on shares of Biogen from $295.00 to $290.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 14th. Nine equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $305.68.
Read Our Latest Stock Report on Biogen
Institutional Trading of Biogen
Several institutional investors have recently added to or reduced their stakes in the stock. ICICI Prudential Asset Management Co Ltd raised its holdings in shares of Biogen by 15.0% during the fourth quarter. ICICI Prudential Asset Management Co Ltd now owns 35,989 shares of the biotechnology company's stock worth $9,313,000 after purchasing an additional 4,693 shares during the period. Boone Capital Management LLC grew its position in Biogen by 52.9% in the 3rd quarter. Boone Capital Management LLC now owns 96,115 shares of the biotechnology company's stock valued at $24,703,000 after buying an additional 33,238 shares in the last quarter. iA Global Asset Management Inc. grew its position in Biogen by 35.2% in the 3rd quarter. iA Global Asset Management Inc. now owns 12,071 shares of the biotechnology company's stock valued at $3,102,000 after buying an additional 3,145 shares in the last quarter. Illinois Municipal Retirement Fund grew its position in Biogen by 13.8% in the 3rd quarter. Illinois Municipal Retirement Fund now owns 68,391 shares of the biotechnology company's stock valued at $17,577,000 after buying an additional 8,291 shares in the last quarter. Finally, Dynamic Advisor Solutions LLC grew its position in Biogen by 6.2% in the 4th quarter. Dynamic Advisor Solutions LLC now owns 4,850 shares of the biotechnology company's stock valued at $1,251,000 after buying an additional 285 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.
About Biogen
(
Get Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
